Searchable abstracts of presentations at key conferences in endocrinology

ea0016p90 | Bone and calcium | ECE2008

Relationship between osteoporosis and living/working environment

Georgiadis A , Tapsis K , Tseronis K , Fillipitzis I , Fitili P , Zervas K , Ziogas A , Karapiperis A , Ntavas E

Osteoporosis can be caused by many miscellaneous factors. These factors include medical, lifestyle and socioeconomic variables, the latest being not well studied and defined in international bibliography. From these there are the factors regarding the working environment (house or office) and the living environment (urban or countryside). Our hypothesis is based on the fact that women living in an urban environment or working in an office environment should have lower Bone Min...

ea0090ep173 | Calcium and Bone | ECE2023

The effect of Immune Checkpoint Inhibitors (ICIs) in Bone Metabolism: A case series analysis

Siampanopoulou Vasiliki , Angelousi Anna , Karampela Athina , Papalexis Petros , Lafioniatis Alexandros , Mytareli Chrysoula , Ziogas Dimitrios , Gogas Helen , Kassi Evanthia

Background: Immune checkpoint inhibitors (ICIs) constitutes a novel treatment for patients with melanoma. Endocrine-related adverse effects are now a distinctive clinical entity of ICIs, with hypophysitis and thyroiditis being the most common. Recent consensus doesn’t suggest routinely screening of bone mass indexes in patients on ICIs since data in the literature are scarce.Methods: Data regarding bone disease were retrospectively analysed in 118 p...

ea0090ep593 | Endocrine-related Cancer | ECE2023

Endocrinopathies in oncological patients treated with immunotherapy: A real world data study

Angelousi Anna , Karampela Athina , Kazanas Spyridon , Papalexis Petros , Lafioniatis Alexandros , Siampanopoulou Vasiliki , Mytareli Chrysoula , Theochari Maria , Stephanou Dimitra , Ziogas Dimitrios , Gogas Helen

Background: Immune checkpoint inhibitors (ICIs) (anti-CTLA-4, PD-1 inhibitors, PD-L1 inhibitors) are considered a widely used therapeutic choice for several cancer types. However ICI therapy is frequently complicated by adverse events; endocrine toxicities are the most common ones.Methods: To assess in a retrospective observational study in a tertiary hospital the incidence and the characteristics of the immunotherapy-related endocrine adverse events (ir...

ea0089c32 | Clinical – Surgery/Applied Pathology | NANETS2022

Surgical Management of G3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis

Ziogas, MD, MPH Ioannis A. , T. Tasoudis, MD Panagiotis , C. Borbon, MD Luis , K. Sherman, MD, FACS Scott , J. Breheny, MS, PhD Patrick , Chandrasekharan, MBBS Chandrikha , S. Dillon, MD Joseph , M. Bellizzi, MD Andrew , R. Howe, MD, FACS James

Background: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) are rare, aggressive tumors with poor prognosis. The WHO 2017 classification further subdivided G3 NENs into G3 neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). Current guidelines favor medical management in most of these patients, and the role of surgical management is not well-defined. We performed a systematic literature review and meta-analysis of surgical management vs ...